WSD0922-FU

WSD0922-FU · Wayshine Biopharm, Inc.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for WSD0922-FU, covering 2025-08-29 to 2026-03-30. Get the full timeline:

Most recent: Clinical Trial Update: WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases [Phase 1]

See pricing